Cassava Sciences IncNASDAQ:SAVA
- LAST PRICE22.0000
- TODAY'S CHANGE (%)0.4400 (2.0408%)
- Bid / Lots21.9600/ 1
- Ask / Lots22.0000/ 1
- Open / Previous Close22.1200 / 21.5600
- Day Range
- 52 Week Range
- Volume171,781
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | SAVA |
|---|---|---|
| 09:32 ET | 26492 | 22.1865 |
| 09:34 ET | 2424 | 21.87 |
| 09:36 ET | 3100 | 21.9 |
| 09:38 ET | 3149 | 21.885 |
| 09:39 ET | 1027 | 21.78 |
| 09:41 ET | 6932 | 21.71 |
| 09:43 ET | 6354 | 21.7 |
| 09:45 ET | 600 | 21.7 |
| 09:48 ET | 1100 | 21.7067 |
| 09:50 ET | 4046 | 21.62 |
| 09:52 ET | 13862 | 21.4589 |
| 09:54 ET | 4525 | 21.4779 |
| 09:56 ET | 1200 | 21.41 |
| 09:57 ET | 2690 | 21.54 |
| 09:59 ET | 2610 | 21.54 |
| 10:01 ET | 1017 | 21.58 |
| 10:03 ET | 420 | 21.6499 |
| 10:06 ET | 3540 | 21.73 |
| 10:08 ET | 2604 | 21.76 |
| 10:10 ET | 200 | 21.6212 |
| 10:12 ET | 252 | 21.67 |
| 10:14 ET | 373 | 21.76 |
| 10:15 ET | 3150 | 21.9163 |
| 10:17 ET | 3453 | 22 |
| 10:19 ET | 2007 | 22.02 |
| 10:21 ET | 1800 | 21.95 |
| 10:24 ET | 2024 | 21.985 |
| 10:26 ET | 3425 | 21.92 |
| 10:28 ET | 849 | 22.02 |
| 10:30 ET | 395 | 21.99 |
| 10:32 ET | 1915 | 22.0007 |
| 10:33 ET | 500 | 21.995 |
| 10:35 ET | 300 | 21.995 |
| 10:42 ET | 323 | 22.01 |
| 10:44 ET | 3112 | 22.1499 |
| 10:46 ET | 11070 | 22.0509 |
| 10:48 ET | 1099 | 22.04 |
| 10:50 ET | 1696 | 22.0099 |
| 10:53 ET | 525 | 21.9973 |
| 10:55 ET | 250 | 21.9991 |
| 10:57 ET | 600 | 21.97 |
| 11:00 ET | 340 | 21.9713 |
| 11:02 ET | 200 | 21.93 |
| 11:06 ET | 400 | 21.89 |
| 11:08 ET | 300 | 21.925 |
| 11:09 ET | 100 | 21.9 |
| 11:11 ET | 300 | 21.85 |
| 11:13 ET | 947 | 21.91 |
| 11:15 ET | 1584 | 21.938 |
| 11:20 ET | 127 | 22 |
| 11:22 ET | 103 | 21.995 |
| 11:24 ET | 978 | 21.995 |
| 11:26 ET | 2076 | 22.04 |
| 11:29 ET | 499 | 22.0003 |
| 11:31 ET | 104 | 21.98 |
| 11:33 ET | 1000 | 22.0199 |
| 11:36 ET | 100 | 22 |
Today
DJ Cassava Sciences Is Maintained at Buy by HC Wainwright & Co., from 3 hours ago by Dow Jones
3 hours ago by Dow Jones
May 10, 2024
Cassava Sciences Reports Q1 2024 Financial Results and Clinical Updates on Phase 3 Trials of Simufilam, from 4:02PM ET on Friday May 10, 2024 by Dow Jones
4:02PM ET on Friday May 10, 2024 by Dow Jones*DJ Cassava Sciences 1Q Loss/Shr 43c >SAVA, from 4:02PM ET on Friday May 10, 2024 by Dow Jones
4:02PM ET on Friday May 10, 2024 by Dow Jones
May 8, 2024
Cassava Sciences Announces Over $125 Million Raised from Warrant Distribution, from 11:00AM ET on Wednesday May 08, 2024 by Dow Jones
11:00AM ET on Wednesday May 08, 2024 by Dow Jones
May 1, 2024
Tomorrow is Last Day to Trade SAVAW Warrants on NASDAQ, from 9:10AM ET on Wednesday May 01, 2024 by Dow Jones
9:10AM ET on Wednesday May 01, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Cassava Sciences Inc | 1.0B | -18.8x | --- |
Tyra Biosciences Inc | 1.0B | -11.1x | --- |
Verona Pharma PLC | 1.1B | -16.7x | --- |
Autolus Therapeutics PLC | 1.1B | -3.8x | --- |
Centessa Pharmaceuticals PLC | 1.0B | -6.3x | --- |
Enliven Therapeutics Inc | 1.1B | -10.7x | --- |
Company Information
Cassava Sciences, Inc. is a biotechnology company focused on Alzheimer's disease. The Company's science is based on stabilizing, but not removing, a critical protein in the brain. The Company is focused on its product discovery and development efforts on disorders of the nervous system. Its lead therapeutic drug candidate, simufilam, is under clinical evaluation for the proposed treatment of Alzheimer's disease dementia in Phase 3 clinical studies. The Company has two biopharmaceutical assets under development. Its lead therapeutic product candidate, called simufilam, is an oral treatment for Alzheimer's disease dementia. Its lead investigational diagnostic product candidate, called SavaDx, is a way to detect the presence of Alzheimer's disease from a small sample of blood. Simufilam targets an altered form of a protein called filamin A in the Alzheimer's brain. It owns rights to its drug and diagnostic assets and related technologies, without royalty obligations to any third party.
Contact Information
- Headquarters
- 6801 N CAPITAL OF TEXAS HIGHWAY BUILDING 1; SUITE 300AUSTIN, TX, United States 78731
- Phone
- 512-501-2444
- Fax
- 512-614-0414
Executives
- Chairman of the Board, President, Chief Executive Officer
- Remi Barbier
- Chief Financial Officer
- Eric Schoen
- Senior Vice President, General Counsel
- R. Christopher Cook
- Chief Medical Officer
- James Kupiec
- Lead Independent Director
- Sanford Robertson
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $1.0B |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 48.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | -0.50 |
EPS | $-1.17 |
Book Value | $3.25 |
P/E Ratio | -18.8x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
